文献速递脊柱关节炎

阿达木单抗抑制银屑病关节炎影像学进展独立于临床疾病活动度控制

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-01

该研究为ADEPT试验的事后分析,评估阿达木单抗(ADA)或安慰剂(PBO)治疗的银屑病关节炎(PsA)患者中影像学进展与疾病活动度的关系及甲氨蝶呤(MTX)的影响。结果显示,无论是否联用MTX,ADA组各疾病活动度类别的ΔmTSS均低于PBO组;即使在中等/高疾病活动度或未达到MDA者中,ADA组ΔmTSS仍显著更低。结论认为ADA抑制影像学进展的程度超出仅基于临床疾病活动度控制的预期,存在「脱节」现象,MTX无额外效应。

要点

  • ADA抑制影像学进展独立于临床疾病活动度控制,存在「脱节」现象。
  • 联用MTX对影像学进展无额外影响。
  • 即使疾病活动度未控制,ADA仍显著抑制影像学进展。

核心结论

  • 在ADA治疗的PsA患者中,疾病活动度与影像学进展之间存在「脱节」:影像学进展的抑制程度超出仅基于临床疾病活动度控制的预期,MTX无额外效应。

研究设计与样本

  • 随机、双盲、安慰剂对照ADEPT试验的事后分析,受试者按时间平均疾病活动度(基于DAS28(CRP)、DAPSA或PASDAS)及第24周达到MDA分类,评估基线至第24周mTSS变化(ΔmTSS)。

主要发现

  • 时间平均疾病活动度与治疗对ΔmTSS的交互项显著(P=0.002-0.008)。
  • 无论是否联用MTX,ADA组各疾病活动度类别的ΔmTSS均低于PBO组。
  • 即使在中等或高疾病活动度或未达到MDA的受试者中,ADA组ΔmTSS仍显著低于PBO组(TA-DAPSA、TA-PASDAS和MDA的P=0.05-0.001)。
  • 时间平均疾病活动度评分与ΔmTSS的相关性在PBO组呈中度正相关且显著(P<0.001),在ADA组不显著。

临床怎么用

  • 对于PsA患者,ADA抑制影像学进展的作用不完全依赖于临床疾病活动度的控制,即使疾病活动度未达标仍可能获益。
  • 联用MTX对ADA抑制影像学进展无额外影响。

局限性

  • 本研究为ADEPT试验的事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the relationship between radiographic progression and disease activity in subjects with PsA treated with adalimumab (ADA) or placebo (PBO) and the impact of concomitant MTX. METHODS: This was a post hoc analysis of the randomized, double-blind, PBO-controlled ADEPT trial. Subjects were categorized according to time-averaged (TA) disease activity (remission, low, moderate or high) based on Disease Activity Score of 28 joints with CRP [DAS28(CRP)], Disease Activity Index for Psoriatic Arthritis (DAPSA) or Psoriatic Arthritis Disease Activity Score (PASDAS), and achievement of minimal disease activity (MDA) at week 24. Radiographic progression was assessed as change in modified total Sharp score (ΔmTSS) from baseline to week 24. The analyses included interaction terms between disease activity and treatment on radiographic progression, comparison of radiographic progression in subjects categorized by disease activity and treatment, and correlation between disease activity and radiographic progression by treatment. RESULTS: The interaction terms for TA disease activity and treatment on ΔmTSS were significant (P = 0.002-0.008). Irrespective of concomitant MTX, ΔmTSS was lower with ADA vs PBO in all disease activity categories. Importantly, even in subjects having moderate or high disease activity or not achieving MDA, ΔmTSS was significantly lower on ADA than PBO (P = 0.05-0.001 for TA-DAPSA, TA-PASDAS and MDA). Correlations between TA disease activity scores and ΔmTSS were moderately positive and significant (P < 0.001) with PBO but non-significant with ADA. CONCLUSION: Among subjects with PsA treated with ADA, there was evidence of a 'disconnect' between disease activity and radiographic progression: inhibition of radiographic progression was greater than expected based on control of clinical disease activity alone. MTX had no added effect. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT00646386.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Landewé R, Ritchlin CT, Aletaha D, et al. Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity. Rheumatology (Oxford). 2019. PMID: 30608620. doi:10.1093/rheumatology/key417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。